Mounia Chaoui-Roulleau
Direktor/Vorstandsmitglied bei Institut National de la Santé & de la Recherche Médicale
Ursprung des Netzwerks ersten Grades von Mounia Chaoui-Roulleau
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
Turenne Capital Partenaires SA
 Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France.
44
| Subsidiary | Investment Managers | 44 |
École Centrale Paris
23
| College/University | Other Consumer Services | 23 |
Institut National de la Santé & de la Recherche Médicale
 Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.
17
| Subsidiary | Miscellaneous Commercial Services | 17 |
Sofimac Innovation SAS
 Sofimac Innovation SAS Investment ManagersFinance Sofimac Innovation SAS is an independent, early-stage venture capital firm which was created in 1998 by Eric Harlé and Didier Moret. Headquartered in Paris, France, Sofimac Innovation manages venture capital funds which provide equity financing for start-ups and early-stage companies in the Information and Communication Technologies (Software, SaaS, Multimedia and Telecom) sector.
15
| Subsidiary | Investment Managers | 15 |
Intrexon ActoBiotics NV
 Intrexon ActoBiotics NV BiotechnologyHealth Technology Intrexon ActoBiotics NV manufactures biopharmaceutical products. It focuses on the development and commercialization of a new generation of biological drugs. The company represents a novel concept for oral administration of therapeutic proteins, and is designed to be safer and more effective than injectable biopharmaceuticals. Intrexon Actobioticswas founded by Mark Vaeck, Emil Pot and Bernard Coulie in June 2006 and is headquartered in Zwijnaarde, Belgium.
15
| Subsidiary | Biotechnology | 15 |
Ventech SA
 Ventech SA Investment ManagersFinance Ventech SA is part of the venture capital arm and a wholly-owned subsidiary of Natixis Private Equity (NPE), which in turn is a subsidiary of Paris-based Natixis SA (XP: KN). Ventech was established in 1998 and is located in Paris. The firm specializes in technology venture capital investing. Ventech manages venture capital funds for a clientele of European institutional investors, with NPE as their sponsor. The firm relies on international strategic alliances with seeding funds and venture capital firms in Germany, Switzerland, Israel, Japan and the US.
11
| Subsidiary | Investment Managers | 11 |
Eye Tech Care SA
 Eye Tech Care SA Medical SpecialtiesHealth Technology Eye Tech Care SA develops medical devices for non-invasive eye disease treatment. It offers an ultrasound device which offers a non-invasive treatment that utilizes the ultrasound circular cyclo-coagulation procedure that reduces the intraocular pressure in refractory glaucoma. The firm serves the ophthalmology market in France and Europe. The company was founded by Fabrice Romano, Laurent Farcy and Philippe Chapuis in 2008 and is headquartered in Rillieux-la-Pape, France.
9
| Holding Company | Medical Specialties | 9 |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria.
8
| Subsidiary | Pharmaceuticals: Major | 8 |
Millendo Therapeutics SAS
 Millendo Therapeutics SAS Medical SpecialtiesHealth Technology Millendo Therapeutics SAS provides pharmaceutical research services. It engages in the development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases and rare diseases. The company was founded by Thierry Abribat, André de Villers, Ezio Ghigo and Aart Jan van der Lely on April 23, 2007 and is headquartered in Ecully, France.
7
| Subsidiary | Medical Specialties | 7 |
| Public Company | Pharmaceuticals: Major | 6 | |
Physio-Assist SAS
 Physio-Assist SAS Medical SpecialtiesHealth Technology Physio-Assist SAS develops an expertise in bronchial mucus analysis and clearance. The company was founded by Adrien Mithalal on September 17, 2012 and is headquartered in Aix en Provence, France.
4
| Subsidiary | Medical Specialties | 4 |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.
3
| Subsidiary | Pharmaceuticals: Generic | 3 |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
| Public Company | Pharmaceuticals: Major | 2 | |
Funxional Therapeutics Ltd.
 Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom.
1
| Extinct | Pharmaceuticals: Major | 1 |
INSERM Transfert SA
 INSERM Transfert SA Investment ManagersFinance INSERM Transfert SA is a Venture Capital firm, a subsidiary of Institut National de la Sant? et de la Recherche M?dicale founded in 2000. INSERM Transfert SA is headquartered in Paris, France.
1
| Extinct | Investment Managers | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Mounia Chaoui-Roulleau
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ALTUR INVESTISSEMENT | Investment Managers | Corporate Officer/Principal Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Chief Investment Officer | |
| THERATECHNOLOGIES INC. | Pharmaceuticals: Major | Founder Chief Tech/Sci/R&D Officer Chief Tech/Sci/R&D Officer Director/Board Member Corporate Officer/Principal | |
Vlaams Instituut voor Biotechnologie - Flanders Institute
 Vlaams Instituut voor Biotechnologie - Flanders Institute Other Consumer ServicesConsumer Services Vlaams Instituut voor Biotechnologie - Flanders Institute operates as a non-profit organization, provides research and development services. It specializes in translating basic scientific results into pharmaceutical, agricultural and industrial applications. The company was founded on January 1, 1996 and is headquartered in Ghent, Belgium. | College/University | Chief Executive Officer Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Ghent University | College/University | Graduate Degree Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree | |
| Université Catholique de Louvain | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree Doctorate Degree | |
CropDesign NV
 CropDesign NV Miscellaneous Commercial ServicesCommercial Services CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director of Finance/CFO Director of Finance/CFO | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
FlandersBio vzw
 FlandersBio vzw Miscellaneous Commercial ServicesCommercial Services FlandersBio vzw is a life sciences cluster organization based in Flanders, Belgium. FlandersBio creates value by organizing networking and training activities, supporting internationalization, providing services, and building expertise. The Belgian company was founded by Jean Marie Stassen. | Miscellaneous Commercial Services | Director/Board Member Chairman Chairman | |
| École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin Masters Business Admin Undergraduate Degree | |
| Nord Capital Partenaires SAS | Investment Managers | Chief Executive Officer Chief Executive Officer Private Equity Investor | |
Amolyt Pharma SAS
 Amolyt Pharma SAS Pharmaceuticals: MajorHealth Technology Amolyt Pharma SAS engages in development of biopharmaceutical drugs, proteins and peptides for the treatment of metabolic diseases. The company was founded by Thierry Abribat in 2014 and is headquartered in Ecully, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Founder | |
| ESSEC Business School | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| BIOM'UP | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
Q-Biologicals NV
 Q-Biologicals NV BiotechnologyHealth Technology Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| BIOMÉRIEUX | Medical Specialties | Chief Tech/Sci/R&D Officer Director/Board Member | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
NEURONAX SA
 NEURONAX SA Pharmaceuticals: MajorHealth Technology NEURONAX SA develops and provides drugs supporting neural repair to treat degenerative disorders of the central nervous system. Its services include cell culture, in vitro evaluation, neurotrophic and neuroprotective effects analysis, culture analyses, and stem cells. The company was founded by Stéphane Gobron, Fabrice Cailloux, and Pierre-Yves Simonin in 2003 and is headquartered in Saint-Beauzire, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Trace One SAS
 Trace One SAS Packaged SoftwareTechnology Services Trace One SA provides e-collaborative solutions for private label. It specializes in retail, food safety, product development, private label collaboration platform, collaborative retail network, consumer packaged goods. The company was founded by Jérôme Malavoy in 2001 and is headquartered in Paris, France. | Packaged Software | Director/Board Member Director/Board Member | |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Biotechnology | Founder Corporate Officer/Principal | |
| INSEAD | College/University | Masters Business Admin Undergraduate Degree | |
LeddarTech, Inc.
 LeddarTech, Inc. Packaged SoftwareTechnology Services LeddarTech, Inc. develops and markets 3D detection and tracking systems. The firm?s solutions include auto and mobility LiDAR platform, mobility LiDAR and Specialty LiDAR modules, Sensor fusion and perception. It also offers its applications for passenger cars, autonomous shuttles, robotaxi, commercial and delivery vehicles. The company was founded by Yvan Mimeault, David Gilbert and Marc Tremblay in 2007 and is headquartered in Quebec, Canada. | Packaged Software | Director/Board Member Director/Board Member | |
MaSTherCell SA
 MaSTherCell SA BiotechnologyHealth Technology MaSTherCell SA engages in providing cell therapy manufacturing services. The company was founded in 2011 and is headquartered in Charleroi, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Smartesting Solutions & Services SAS
 Smartesting Solutions & Services SAS Packaged SoftwareTechnology Services Smartesting Solutions & Services SAS designs and develops software solutions to handle certification and testing of computer applications. It provides a certification approach that automates the production of required functional tests and helps reduce the risks of testing the most critical business applications. The company was founded in 2003 by Bruno Legeard and Laurent Py and is headquartered in Besancon, France. | Packaged Software | Director/Board Member Director/Board Member | |
Mablink Bioscience
 Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| OSE IMMUNOTHERAPEUTICS | Pharmaceuticals: Major | Chief Operating Officer Director/Board Member | |
Centre National de la Recherche Scientifique
 Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Corporate Officer/Principal Corporate Officer/Principal | |
| OXURION NV | Pharmaceuticals: Major | Director of Finance/CFO Chairman | |
| Vlerick Leuven Gent Management School | College/University | Masters Business Admin Masters Business Admin | |
| University of Antwerp | College/University | Graduate Degree Graduate Degree | |
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Biotechnology | Chief Executive Officer Chief Executive Officer | |
Imcheck Therapeutics SAS
 Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
keepMED Ltd.
 keepMED Ltd. Medical SpecialtiesHealth Technology keepMED Ltd. manufactures innovative devices for treating obstructive sleep apnea. It offers keePAP, a wearable device that comprises of a lightweight unobtrusive nasal interface and a miniature battery-operated control unit that is used for the treatment of obstructive sleep apnea. The company was founded by Rapoport Alex and is headquartered in Rishon Le Zion, Israel. | Medical Specialties | Chairman Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer General Counsel | |
Confo Therapeutics NV
 Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Masters Business Admin Masters Business Admin | |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University College Cork | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Université Libre de Bruxelles | College/University | Undergraduate Degree Doctorate Degree | |
Lytess SA
 Lytess SA Apparel/FootwearConsumer Non-Durables Lytess SA produces and sells health and beauty cosmetic textile products. It offers Slim Express, a shaping textile with a micro-encapsulated slimming serum; Stop Cellulite, a micro-massaging product for an anti-cellulite treatment and Sculpt & Slim, a corrective and slimming shapewear for immediate and slimming effect. The company was founded in 2003 by Philippe Andrieu and is headquartered in Fondettes, France. | Apparel/Footwear | Director/Board Member Director/Board Member | |
Ipsen NV
 Ipsen NV Pharmaceuticals: MajorHealth Technology Part of Ipsen SA, Ipsen NV is a Belgian biopharmaceutical company that improves patients' lives through research and innovation in oncology, rare disease, and neuroscience. Founded in 1982, the company is based in Merelbeke, Belgium. Ipsen is a global mid-sized biopharmaceutical company that focuses on improving patients' lives through its research and innovation in the field of oncology, rare diseases, and neuroscience. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Pfizer NV/SA | Corporate Officer/Principal Corporate Officer/Principal | ||
| Université Paris 1 Panthéon-Sorbonne | College/University | Graduate Degree Masters Business Admin | |
JenaValve Technology GmbH
 JenaValve Technology GmbH Medical SpecialtiesHealth Technology JenaValve Technology GmbH develops and manufactures transcatheter valve implantation systems for transapical and transfemoral implantation. The firm offers a therapeutic alternative to surgical aortic valve replacement for high-risk patients suffering from aortic heart valve stenosis. The company was founded by Markus Ferrari, Volker Guyenot and Hans-Reiner Figulla in 2006 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member Corporate Officer/Principal |
Statistik
International
| Frankreich | 23 |
| Belgien | 19 |
| Schweiz | 4 |
| Kanada | 3 |
| Vereinigte Staaten | 3 |
Sektoral
| Health Technology | 27 |
| Consumer Services | 13 |
| Finance | 4 |
| Technology Services | 4 |
| Commercial Services | 3 |
Operativ
| Director/Board Member | 382 |
| Corporate Officer/Principal | 137 |
| Chairman | 69 |
| Chief Executive Officer | 61 |
| Private Equity Investor | 57 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| François Miceli | 43 |
| Chris Buyse | 39 |
| Bernard Chauvin | 34 |
| Regina Hodits | 34 |
| Patrick van Beneden | 32 |
| Bernard Gilly | 32 |
| Jean-Paul Prieels | 32 |
| Staf van Reet | 22 |
| Johan Cardoen | 22 |
| François Lombard | 19 |
| Philippe Dro | 18 |
| Gilles Alberici | 18 |
| Jos Sluys | 17 |
| Marco Taglietti | 16 |
| Karl Nägler | 16 |
- Börse
- Insiders
- Mounia Chaoui-Roulleau
- Unternehmensverbindungen
